Edition:
United States

Rocket Pharmaceuticals Inc (RCKT.OQ)

RCKT.OQ on NASDAQ Stock Exchange Global Market

14.30USD
3:59pm EST
Change (% chg)

$-0.40 (-2.72%)
Prev Close
$14.70
Open
$14.77
Day's High
$15.12
Day's Low
$14.07
Volume
105,026
Avg. Vol
79,058
52-wk High
$25.85
52-wk Low
$9.60

Latest Key Developments (Source: Significant Developments)

Rocket Pharmaceuticals receives FDA regenerative medicine advanced therapy (rmat) and fast track designations for rp-l102 gene therapy for fanconi anemia
Tuesday, 27 Nov 2018 07:00am EST 

Nov 27 (Reuters) - Rocket Pharmaceuticals Inc ::ROCKET PHARMACEUTICALS RECEIVES FDA REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) AND FAST TRACK DESIGNATIONS FOR RP-L102 GENE THERAPY FOR FANCONI ANEMIA.ROCKET PHARMACEUTICALS INC - GLOBAL TRIAL OF RP-L102 UTILIZING NO CONDITIONING AND "PROCESS B" ON TRACK FOR EARLY 2019.  Full Article

Rocket Pharmaceuticals Announces Clearance Of IND For RP-L201 Gene Therapy
Monday, 19 Nov 2018 07:00am EST 

Nov 19 (Reuters) - Rocket Pharmaceuticals Inc ::ROCKET PHARMACEUTICALS ANNOUNCES CLEARANCE OF IND FOR RP-L201 GENE THERAPY FOR LEUKOCYTE ADHESION DEFICIENCY-I (LAD-I).ROCKET PHARMACEUTICALS INC - PHASE 1/2 CLINICAL TRIAL IN SUPPORT OF REGISTRATION TO COMMENCE IN U.S. IN 2019.  Full Article

Rocket Pharmaceuticals Gets FDA Clearance Of IND Application For RP-L102 Gene Therapy For Fanconi Anemia
Wednesday, 7 Nov 2018 07:00am EST 

Nov 7 (Reuters) - Rocket Pharmaceuticals Inc ::ROCKET PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR RP-L102 GENE THERAPY FOR FANCONI ANEMIA.ROCKET PHARMACEUTICALS INC - U.S. TRIAL TO COMMENCE EARLY 2019; NO CONDITIONING REQUIRED.  Full Article

Rocket Pharmaceuticals Reports Q1 Loss Per Share Of $0.42
Friday, 11 May 2018 07:00am EDT 

May 11 (Reuters) - Rocket Pharmaceuticals Inc ::ROCKET PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS.Q1 LOSS PER SHARE $0.42.  Full Article

Rocket Pharmaceuticals Reports Full-Year 2017 Results
Tuesday, 6 Mar 2018 07:00am EST 

March 6 (Reuters) - Rocket Pharmaceuticals Inc ::ROCKET PHARMACEUTICALS REPORTS FULL YEAR 2017 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS.ROCKET PHARMACEUTICALS INC - CASH AS OF DECEMBER 31, 2017 FOR ROCKET PHARMACEUTICALS LTD. WAS $18.1 MILLION.  Full Article

Inotek files for preliminary proxy statement for proposed merger with Rocket Pharmaceuticals
Thursday, 12 Oct 2017 05:20pm EDT 

Oct 12 (Reuters) - Inotek Pharmaceuticals Corp :Inotek Pharmaceuticals announces filing of preliminary proxy statement for proposed merger with clinical-stage gene therapy company, Rocket Pharmaceuticals.Inotek Pharmaceuticals Corp - ‍additional first-in-human results from up to three programs expected in 2018​.Inotek Pharmaceuticals Corp - ‍merger is expected to close in Q1 of 2018​.  Full Article

‍Adage Capital Partners reports 5.55 pct stake in Inotek Pharmaceuticals
Thursday, 5 Oct 2017 10:52am EDT 

Oct 5 (Reuters) - Inotek's :‍Adage Capital Partners reports 5.55 percent stake in Inotek Pharmaceuticals as of September 26 - SEC filing​.‍Adage Capital Partners says acquired shares of Inotek Pharma because they represent an "attractive investment opportunity"​.‍Adage Capital Partners - Acquired shares of Inotek's common stock pursuant to investment strategies, including merger arbitrage and event driven strategies​.  Full Article

Braden Leonard reports 5.6 pct passive stake in Inotek Pharmaceuticals as of Sept 13 - SEC Filing
Wednesday, 20 Sep 2017 04:16pm EDT 

Sept 20 (Reuters) - Inotek Pharmaceuticals Corp :Braden M Leonard reports 5.6 percent passive stake in Inotek Pharmaceuticals Corp as of Sept 13, 2017 - SEC Filing.  Full Article

Inotek Pharmaceuticals announces merger agreement with Rocket Pharmaceuticals to advance pipeline of first-in-class gene therapies for rare diseases
Tuesday, 12 Sep 2017 04:15pm EDT 

Sept 12 (Reuters) - Inotek Pharmaceuticals Corp :Inotek Pharmaceuticals announces merger agreement with Rocket Pharmaceuticals to advance pipeline of first-in-class gene therapies for rare diseases.Inotek Pharmaceuticals Corp - ‍Rocket shareholders are expected to own approximately 81% of combined company​.Inotek Pharmaceuticals Corp - ‍Shareholders of Rocket will receive shares of newly issued inotek common shares in a private placement​.Says transaction has been unanimously approved by board of directors of both companies.Inotek Pharmaceuticals Corp - ‍Current Inotek shareholders will own approximately 19% of combined company​.Inotek Pharmaceuticals Corp - ‍It is reducing its workforce by approximately 60% to a total of 7 full-time employees​.Inotek Pharmaceuticals Corp - ‍All affected employees are being offered severance and transition benefits​.Inotek Pharmaceuticals Corp - ‍Gaurav Shah will serve as chief executive officer of combined company​.Inotek Pharmaceuticals Corp - ‍Combined company board of directors will be chaired by Roderick Wong, managing partner of RTW Investments​.  Full Article

Inotek Pharmaceuticals qtrly loss per share $0.24
Thursday, 3 Aug 2017 04:01pm EDT 

Aug 3 (Reuters) - Inotek Pharmaceuticals Corp :Inotek Pharmaceuticals Corporation reports second quarter 2017 financial results and operational highlights.Qtrly loss per share $0.24.  Full Article